Rani Therapeutics Announces New Securities Purchase Agreement

Rani Therapeutics Holdings ( (RANI) ) has issued an announcement.

On July 14, 2025, Rani Therapeutics Holdings entered into a securities purchase agreement with an institutional investor to issue and sell 4,354,000 shares of Class A common stock and pre-funded warrants for 3,146,000 shares, expecting gross proceeds of approximately $3 million. The offering is set to close around July 16, 2025, with Rani agreeing to certain restrictions on issuing additional shares and engaging in new variable rate transactions for a specified period. Additionally, Rani suspended its prospectus supplement related to a previous sales agreement, indicating a strategic shift in its financing approach.

The most recent analyst rating on (RANI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Rani Therapeutics Holdings stock, see the RANI Stock Forecast page.

Spark’s Take on RANI Stock

According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.

Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.

To see Spark’s full report on RANI stock, click here.

More about Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates in the biopharmaceutical industry, focusing on the development of innovative oral biologics through its proprietary RaniPill capsule technology. The company aims to transform the administration of biologics from injections to oral pills, targeting a wide range of therapeutic areas.

Average Trading Volume: 1,711,090

Technical Sentiment Signal: Sell

Current Market Cap: $44.14M

For detailed information about RANI stock, go to TipRanks’ Stock Analysis page.